Liver Transplantation in Adults With Wilson’s Disease for the Neuropsychiatric Phenotype: Are We There Yet?
Mohamed A. Abdallah, Ashwani K. Singal – 7 February 2020
Chronic Kidney Disease in Cirrhosis: Emerging Complication With Negative Impact in the Liver Transplant Setting
Elsa Solà, Pere Ginès – 7 February 2020
Liquid Biopsies for Hepatocellular Cancer and Their Potential in Clinical Practice
Gary P. Jeffrey, Louisa G. Gordon, Michelle M. Hill, Grant A. Ramm – 7 February 2020
PORTICO: First Randomized Controlled Trial of Vasomodulator Therapy in Portopulmonary Hypertension
Sarah Raevens, Michael B. Fallon – 7 February 2020
Primary Alcohol‐Activated Human and Mouse Hepatic Stellate Cells Share Similarities in Gene‐Expression Profiles
Xiao Liu, Sara Brin Rosenthal, Nairika Meshgin, Jacopo Baglieri, Sami G. Musallam, Karin Diggle, Kevin Lam, Raymond Wu, Stephanie Q. Pan, Yibu Chen, Ken Dorko, Sharon Presnell, Chris Benner, Mojgan Hosseini, Hidekazu Tsukamoto, David Brenner, Tatiana Kisseleva – 6 February 2020 – Alcoholic liver disease (ALD) is a leading cause of cirrhosis in the United States, which is characterized by extensive deposition of extracellular matrix proteins and formation of a fibrous scar. Hepatic stellate cells (HSCs) are the major source of collagen type 1 producing myofibroblasts in ALD fibrosis.
PDK4‐Deficiency Reprograms Intrahepatic Glucose and Lipid Metabolism to Facilitate Liver Regeneration in Mice
Yulan Zhao, Melanie Tran, Li Wang, Dong‐Ju Shin, Jianguo Wu – 5 February 2020 – Liver regeneration requires intrahepatic and extrahepatic metabolic reprogramming to meet the high hepatic bioenergy demand for liver cell repopulation. This study aims to elucidate how pyruvate dehydrogenase kinase 4 (PDK4), a critical regulator of glucose and lipid metabolism, coordinates metabolic regulation with efficient liver growth. We found that hepatic Pdk4 expression was elevated after two‐thirds partial hepatectomy (PHx).
Reply
Hye‐Mee Kwon, Gyu‐Sam Hwang – 5 February 2020
Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes
Yamini Natarajan, Jennifer R. Kramer, Xian Yu, Liang Li, Aaron P. Thrift, Hashem B. El‐Serag, Fasiha Kanwal – 5 February 2020
Letter to the Editor: Appraisal of Cardiac Ejection Fraction With Liver Disease Severity
Won Ho Kim, Seong‐Mi Yang, Kook Hyun Lee – 5 February 2020
Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda
Philip Grant, Fabienne Shumbusho, Jennifer Ilo Van Nuil, Fredrick Kateera, Joia Mukherjee, Jules Kabahizi, Fabien Ntaganda, Sabin Nsanzimana, Aimable Mbituyumuremyi, Makuza Jean Damascene, Claude Mambo Muvunyi, Constance Mukabatsinda, Emmanuel Musabeyezu, Cyprien Ntirenganya, Neil Gupta – 4 February 2020 – Direct‐acting antivirals for hepatitis C virus (HCV) are highly effective and well‐tolerated. However, only a small percentage of HCV‐infected individuals globally have received therapy.